Dyanavel XR (amphetamine XR) / Tris Pharma  >>  Phase 4
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Dyanavel XR (amphetamine XR) / Tris Pharma
NCT03610464: Pharmacokinetic Study of DYANAVEL XR (Amphetamine) Extended-release Oral Suspension, in Children Aged 4 to 5 Years

Completed
4
5
US
Amphetamine Extended Release Suspension [Dyanavel], DYANAVEL XR, amphetamine extended release oral suspension
Tris Pharma, Inc.
Attention Deficit Hyperactivity Disorder
05/18
05/18
NCT06248229: A Trial of Dyanavel XR in Treating Co-occurring Fatigue Symptoms in Adults With Attention Deficit Hyperactivity Disorder (ADHD).

Not yet recruiting
4
50
NA
Dyanavel XR, Placebo
Rochester Center for Behavioral Medicine
Fatigue, Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder
09/26
12/26

Download Options